KR890009392A - 인식력 향상제로서 d-시클로세린 및 그의 프로드럭과 사용법 - Google Patents

인식력 향상제로서 d-시클로세린 및 그의 프로드럭과 사용법 Download PDF

Info

Publication number
KR890009392A
KR890009392A KR1019880015895A KR880015895A KR890009392A KR 890009392 A KR890009392 A KR 890009392A KR 1019880015895 A KR1019880015895 A KR 1019880015895A KR 880015895 A KR880015895 A KR 880015895A KR 890009392 A KR890009392 A KR 890009392A
Authority
KR
South Korea
Prior art keywords
hydrido
compound
lower alkyl
alkyl
alkoxyalkyl
Prior art date
Application number
KR1019880015895A
Other languages
English (en)
Other versions
KR0134198B1 (ko
Inventor
에이.코르디 알렉스
이.한델만 게일
비.모나한 조세프
Original Assignee
폴 디.마튜카이티스
지.디.썰 앤드 컴파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴 디.마튜카이티스, 지.디.썰 앤드 컴파니 filed Critical 폴 디.마튜카이티스
Publication of KR890009392A publication Critical patent/KR890009392A/ko
Application granted granted Critical
Publication of KR0134198B1 publication Critical patent/KR0134198B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

인식력 향상제로서 D-시클로세린 및 그의 프로드럭과 사용법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 식
    의 화합물의 군으로부터 선택된 화합물을 치료학적으로 유효한 양으로 동물에게 투여함으로써 인식기능을 향상시키는 것을 특징으로 하는 방법.
    단, 상기 식에서 R1은 히드리도, 알킬, 할로알킬,알콕시알킬, 시클로알킬, 아르알킬 및 아릴에서 선택되고 ; R2는 히드리도, 알킬, 아르알킬, 아릴,로부터 선택되고 ; R1및 R2는 알데히드 및 케톤의 유도체로부터 선택된 시프-염기 유도기를 형성하도록 취해지며 ; R3는 히드리도, 알킬, 할로알킬, 알콕시, 알콕시알킬, 시크로알킬, 아르알킬 및 아릴에서 선택되거나 ; 또는 그의 약학적 허용염이다.
  2. 제 1 항에 있어서, R1은 히드리도, 저급알킬, 할로알킬, 시클로알킬, 알콕시알킬, 페닐알킬 및 페닐로부터 선택되고 ; R2는 히드리도, 저급알킬, 페닐알킬, 페닐,로 부터 선택되고; 시프-염기 유도기는 아세틸아세톤, 살리살알데히드, 벤조페논 유도체 및 아세틸아세트산에스테르로부터 유도되고; R3는 히드리도, 저급알킬 및 벤질로부터 선택되는 것을 특징으로 하는 방법.
  3. 제 2 항에 있어서, R1은 히드리도이고, R2는로 부터 선택되고 ; 시프-염기 유도기는
    로 부터 선택되고 여기서 X 및 Y는 히드리도, 저급알킬 및 할로로부터 각각 독립적으로 선택된 1 또는 그이상의 기이고; R3는 히드리도, 저급알킬 및 페닐로 부터 선택되는 것을 특징으로 하는 방법.
  4. 제 3 항에 있어서, R1은 히드리도 및 시프-염기 유도기
    로 부터 선택되고 여기서 X 및 Y는 플루오로, 클로로 및 브로모로부터 선태고되며; R2및 R3는 각각 히드리도인 것을 특징으로 하는 방법.
  5. 제 4 항에 있어서, 상기 화합물은 D-4-아미노-3-이속사졸리돈인 것을 특징으로 하는 방법.
  6. 식
    의 화합물은 군으로부터 선택된 화합물의 치료학적 유효량으로 이루어진 것을 특징으로 하는 인식기능의 향상에 사용하는 조성물.
    단, 상기 식에서 R1은 히드리도, 알킬, 하로알킬, 알콕시알킬, 시클로알킬, 아르알킬 및 아릴로부터 선택되고; R2는 히드리도, 알킬, 아르알킬, 아릴,로 부터 선택되고; R1및 R2는 알데히드 및 케톤의 유도체로부터 선택된 시프-염기 유도기를 형성하도록 취해지며; R3는 히드리도, 알킬, 할로알킬, 알콕시, 알콕시알킬, 시클로알킬, 아르알킬 및 아릴에서 선택되거나; 또는 그의 약학적 허용염이다.
  7. 제 6 항에 있어서, 상기 식에서 R1은 히드리도, 저급알킬, 할로알킬, 시클로알킬, 알콕시알킬, 페닐알킬 및 페닐로부터 선택되고 ; R2는 히드리도, 저급알킬, 페닐알킬, 페닐,및로부터 선택되고; 시프-염기 유도기는 아세틸아세톤, 살리실알데히드, 벤조페논 유도체 및 아세틸아세트산 에스테르로부터 선택되고; R3는 히드리도, 저급알킬, 및 벤질로부터 선택되는 것을 특징으로 하는 조성물.
  8. 제 7 항에 있어서, R1은 히드리도이고; R-는로부터 선택되고; 시프-염기 유도기는
    로부터 선택되며, 여기서 X 및 Y는 히드리도, 저급알킬 및 할로로부터 각각 독립적으로 선택된 1또는 그이상의 기이고; R3는 히드리도, 저급알킬 및 페닐로부터 선택되는 것을 특징으로 하는 조성물.
  9. 제 8 항에 있어서, R1은 히드리도 및 시프-염기 유도기
    로부터 선택되며 여기서 X 및 Y는 플루오로, 클로로 및 브로모로부터 독립적으로 선택되고; R2및 R3는 히드리도인 것을 특징으로 하는 조성물.
  10. 제 9 항에 있어서, 상기 화합물이 D-4-아미노-3-이속사졸리돈인것을 특징으로 하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880015895A 1987-12-01 1988-11-30 인식력 향상제로서 d-시클로세린 및 그의 프로드럭 KR0134198B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers
US127,121 1987-12-01
US127.121 1987-12-01

Publications (2)

Publication Number Publication Date
KR890009392A true KR890009392A (ko) 1989-08-01
KR0134198B1 KR0134198B1 (ko) 1998-04-21

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880015895A KR0134198B1 (ko) 1987-12-01 1988-11-30 인식력 향상제로서 d-시클로세린 및 그의 프로드럭

Country Status (20)

Country Link
US (1) US4904681A (ko)
EP (2) EP0319824B1 (ko)
JP (2) JPH0621065B2 (ko)
KR (1) KR0134198B1 (ko)
AT (1) ATE68698T1 (ko)
AU (4) AU622630B2 (ko)
CA (1) CA1328617C (ko)
DE (1) DE3865817D1 (ko)
DK (1) DK173589B1 (ko)
ES (1) ES2040314T3 (ko)
FI (1) FI885559A0 (ko)
GR (1) GR3003571T3 (ko)
IE (1) IE61825B1 (ko)
IL (1) IL88531A (ko)
NO (1) NO885337D0 (ko)
NZ (1) NZ227131A (ko)
PH (1) PH26467A (ko)
PT (1) PT89109B (ko)
WO (1) WO1989005144A1 (ko)
ZA (1) ZA888981B (ko)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
AU4128896A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
AU4019395A (en) * 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
WO1997020553A1 (en) * 1995-12-07 1997-06-12 Javitt Daniel C Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US6361957B1 (en) 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
EP2338482A3 (en) * 1998-04-14 2011-12-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
DE69930624T2 (de) * 1998-06-10 2006-09-14 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
US6717012B2 (en) 2001-04-02 2004-04-06 Neuromolecular, Inc. Antioxidant nitroxides and nitrones as therapeutic agents
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
AU2004251636B2 (en) 2003-05-27 2006-11-09 Merz Pharma Gmbh & Co. Kgaa Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
DE602006016934D1 (de) * 2005-04-06 2010-10-28 Adamas Pharmaceuticals Inc Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
AU2009293164B2 (en) 2008-09-18 2015-07-09 Northwestern University NMDA receptor modulators and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
BR112015018087B1 (pt) 2013-01-29 2022-09-20 Aptinyx Inc Compostos moduladores de receptor n-metil-d-aspartato (nmda) de espiro-lactama, composição farmacêutica e uso dos mesmos
PE20151438A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
PE20190502A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung

Also Published As

Publication number Publication date
WO1989005144A1 (en) 1989-06-15
PT89109A (pt) 1989-12-29
IE61825B1 (en) 1994-11-30
JPH05201859A (ja) 1993-08-10
DK669088A (da) 1989-06-02
JPH01193220A (ja) 1989-08-03
EP0319824A1 (en) 1989-06-14
AU2813089A (en) 1989-07-05
DK173589B1 (da) 2001-04-02
IE883567L (en) 1989-06-01
GR3003571T3 (ko) 1993-03-16
ZA888981B (en) 1990-01-31
ES2040314T3 (es) 1995-04-01
DE3865817D1 (ko) 1991-11-28
NO885337D0 (no) 1988-11-30
AU7746794A (en) 1995-01-05
KR0134198B1 (ko) 1998-04-21
JPH0621065B2 (ja) 1994-03-23
ATE68698T1 (de) 1991-11-15
US4904681A (en) 1990-02-27
AU2631988A (en) 1989-06-01
FI885559A0 (fi) 1988-11-30
AU1083992A (en) 1992-05-07
DK669088D0 (da) 1988-11-30
EP0421997A1 (en) 1991-04-17
PT89109B (pt) 1993-07-30
AU622630B2 (en) 1992-04-16
IL88531A (en) 1993-02-21
NZ227131A (en) 1991-09-25
PH26467A (en) 1992-07-27
CA1328617C (en) 1994-04-19
IL88531A0 (en) 1989-06-30
EP0319824B1 (en) 1991-10-23

Similar Documents

Publication Publication Date Title
KR890009392A (ko) 인식력 향상제로서 d-시클로세린 및 그의 프로드럭과 사용법
ES358534A2 (es) Procedimiento para la fabricacion de derivados de alcanolamina
DE69331414T2 (de) Depsipeptide, herstellung und anwendung
ATE219771T1 (de) Carbonsäureanilide, verfahren zu ihrer herstellung und sie enthaltende mittel zur bekämpfung von schadpilzen
SE8005909L (sv) Heterocykliska foreningar och sett for deras framstellning samt fungicida eller vexttillvextreglerande kompositioner, innehallande sadana foreningar, jemte sett att bekempa svampsjukdomar eller reglera tillvexten av ...
ATE55393T1 (de) Wachstumsfoerderungsmittel fuer tiere.
ATE1813T1 (de) 2-aryl-1,3-cyclohexandionverbindungen, deren alkalimetallsalze, ammoniumsalze und enolester, zusammensetzung und verfahren zur bekaempfung von ectoparasitaeren acariden an warmbluetigen tieren.
GB1336098A (en) Benzyl chrysanthemumates
ATE31927T1 (de) (4-oxo-4h-(1)-benzopyran-8-yl)-alkansaueren, salze und derivate, herstellung und diese enthaltende arzneimittel.
ES2036172T3 (es) 1-aril-pirazoles.
ES473287A1 (es) Un procedimiento para la obtencion de nuevos azacicloalcanos
IE40586B1 (en) Aminocarbonylthiobarbituric acid derivatives, process for their preparation and their use as insecticides, and plantprotection agents
ATE62903T1 (de) 1,3-thiazol-insektizidverbindungen.
ATE697T1 (de) Ester von allethrolonderivaten und carbonsaeuren, deren herstellungsverfahren und die sie enthaltenden zusammensetzungen.
ATE18763T1 (de) Diazolyl-alkanole, verfahren zu ihrer herstellung und ihre verwendung als antimykotische mittel.
EP0153582A3 (de) 1,3,2-Dioxaborinane
EP0044976A3 (de) Verwendung von verätherten p-Hydroxyzimtsäureestern als Lichtschutzmittel
DE3688161D1 (de) Gegebenenfalls etherifizierte oder esterifizierte in stellung 2 substituierte 4-oh-chinolincarbonsaeurederivate, verfahren und zwischenprodukte zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
ATE119908T1 (de) 2-formylbenzylphosphonsäure-derivate, deren herstellung und ihre verwendung zur behandlung von durch viren verursachte krankheiten.
GB1302823A (ko)
DE3460039D1 (de) N-sulphenyl-phenethyl sulfonamide
GB1337269A (en) Phosphorus and thiophosphorus acid ester derivatives of substituted hydantoins
KR840001241A (ko) N-알콕시 설페닐 카바메이트의 제조방법
GB1343204A (en) Pesticidal phosphoric ester derivatives
KR890003669A (ko) 제초 활성 페녹시알칸카복실산 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20051014

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee